Lymphoma Working Party Educational Course

Paris, France
5-7 November 2025

WELCOME

The EBMT Lymphoma Working Party Educational Course is a yearly 2-day meeting on transplant and cellular therapy for lymphoproliferative diseases.

The meeting starts with the Scientific Business Meeting, where all current and future studies are discussed. This is a unique opportunity for new or future members of the Working Party to get to know the activities and get involved in ongoing or future projects.

The core programme covers the most frequent types of lymphoma such as Hodgkin lymphoma, aggressive and indolent non Hodgkin lymphomas including mantle cell, peripheral T cell lymphoma and cutaneous T cell lymphoma. One of the sessions also focuses on supportive care in cellular therapy, and the last session covers innovation in allotransplant. Presentations are given by experts with a focus on educational and pedagogic value. Time will also be allocated to interactive case presentations. The programme is built to target a broad audience of trainees, nurses and early to mid-career practitioners interested in lymphoma and cellular therapy.

Yours sincerely,

Ali Bazarbachi — Lymphoma Working Party Chair
Charalampia Kyriakou — Lymphoma Working Party Secretary
Olivier Hermine — Lymphoma Working Party SPC Member and Local Organiser
Anna Sureda — EBMT President & Lymphoma Working Party SPC Member

Lymphoma Working Party Educational Course

Paris, France
5-7 November 2025

Wednesday, 5 November 2025

14:30-18:00	**Lymphoma Working Party Scientific Business Meeting**	

Thursday, 6 November 2025

09:00-09:10	**Welcome from the organizers** Ali Bazarbachi (LB) & Olivier Hermine (FR)	
09:10-11:10	**Session I: Aggressive lymphomas – DLBCL** **Chairs: Bertram Glass (DE) & Christian Gisselbrecht (FR)** This session is kindly supported by Pierre Fabre, which has had no involvement in its selection, development, content or organization of the session	
09:10-09:40	New classifiers: does it matter for treatment	Fabrice Jardin (FR)
09:40-09:50	Discussion	
09:50-10:00	Clonal Evolution and Antigen Escape in Double-Hit DLBCL: An Aggressive Case with Early CAR-T Failure	Igor Kos (DE)
10:00-10:10	From CAR-T Failure to Allogeneic Transplant: Glofitamab-Enabled Remission in Relapsed DLBCL	Taner Tan (TR)
10:10-10:40	Critical discussion of the two cases (10') and CTL anti EBV (20')	Sylvain Choquet (FR)
10:40-11:10	Is there still a role for autologous SCT in DLBCL?	
10:40-10:50	Yes	Christian Gisselbrecht (FR)
10:50-11:00	No	Bertram Glass (DE)
11:00-11:10	Discussion	
11:10-11:40	Coffee break	
11:40-13:00	**Session II: Mantle cell lymphoma** **Chairs: Morgane Cheminant (FR) & Peter Dreger (DE)**	
11:40-12:00	New classifiers: does it matter for treatment	Morgane Cheminant (FR)
12:00-12:10	Successful treatment with CAR T cells for Neurological and CSF Refractory Mantle cell lymphoma	Clémence Loiseau (FR)
12:10-12:30	Discussion of the non-cellular therapy strategics	Olivier Hermine (FR)
12:30-12:50	Discussion of the cellular therapy options: transplant, CART-T and bi-specifics	Peter Dreger (DE)
12:50-13:00	Discussion	
13:00-14:00	Lunch break	
14:00-15:20	**Session III: Indolent B cell lymphoma** **Chairs: Nour Moukalled (LB) & Mahmoud Aljurf (SA)**	
14:00-14:20	New classifiers in follicular lymphoma: does it matter for treatment	Sandrine Roulland (FR)
14:20-14:30	From Indolent to Aggressive: Clinical Insights From A Case of Waldenström's Macroglobulinemia Transformed to High-Grade Lymphoma	Nour Moukalled (LB)
14:30-14:50	Discussion of the non-cellular therapy strategics including bispecifics	Charalampia Kyriakou (UK)
14:50-15:10	Discussion of the cellular therapy options: transplant, CART-T	Silvia Montoto (UK)
15:10-15:20	Discussion	
15:20-16:40	**Session IV: Peripheral T cell lymphoma** **Chairs: Gandhi Damaj (FR) & Olivier Tournilhac (FR)**	
15:20-15:40	New classifiers in TFH: does it matter for treatment	François Lemonnier (FR)
15:40-15:50	Refractory peripheral T cell lymphoma	Julieta Osorio Zuluaga (AE)
15:50-16:10	Standard treatment of the T-cell lymphoma with emphasis on allogeneic and autologous Transplantation + Q&A	Norbert Schmitz (DE)
16:10-16:30	The pipeline of T cell engaging therapy for T cell lymphoma: where do we stand? + Q&A	Pier Luigi Zinzani (IT)
16:30-16:40	Discussion	

Lymphoma Working Party Educational Course

Paris, France
5-7 November 2025

Thursday, 6 November 2025 – continued

16:40-17:10	Coffee break	
17:10-17:50	**Session V: Cutaneous T cell lymphoma** **Chair: Norbert Schmitz (DE)**	
17:10-17:40	CTCL: State-of-the-art treatment and role of cellular therapy	Eva Domingo (ES)
17:40-17:50	Discussion	

Friday, 7 November 2025

09:00-10:30	**Session VI: Hodgkin lymphoma first line** **Chairs: Ali Bazarbachi (LB) & Alina Tanase (RO)**	
09:00-09:20	New classifiers in classical HL: does it matter for treatment	Cédric Rossi (FR)
09:20-09:30	Low-dose nivolumab combined with AVD chemotherapy in newly diagnosed advanced stage classic Hodgkin lymphoma	Mobil Akhmedov (RU)
09:30-09:50	State-of-the-art treatment of NLPHL and role of cellular therapy	Dennis Eichenauer (DE)
09:50-10:20	Choices and options in the first line	Ali Bazarbachi (LB)
10:20-10:30	Discussion	
10:30-11:00	Coffee break	
11:00-12:20	**Session VII: Hodgkin lymphoma in relapse and difficult to treat cases** **Chairs: Ali Bazarbachi (LB) & Luca Castagna (IT)**	
11:00-11:10	Non-Myeloablative Allo-HSCT Using TLI After Failed Autologous Stem Cell Mobilization in Hodgkin Lymphoma	Anisiia Luchkiv (UA)
11:10-11:40	Strategies at relapse	Ali Bazarbachi (LB)
11:40-11:50	Refractory Hodgkin Lymphoma with complex post-allo-HCT course and nivolumab-associated complications	Ludmila Federova (RU)
11:50-12:05	Lung Cancer Screening in Hodgkin Lymphoma Survivors - a UK national initiative	Kim Linton (UK)
12:05-12:20	Discussion	
12:20-13:20	Lunch break	
13:20-14:40	**Session VIII: Supportive care in cellular therapy** **Chairs: Anna Ossami Saidy (DE) & Rémy Duléry (US)**	
13:20-13:30	Severe Neurotoxicity and Spinal Myelopathy Following CD19 CAR-T Therapy in a Patient with Refractory DLBCL: A Case of Complex ICANS and Multidisciplinary Recovery	Amjad Hmaid (UK)
13:30-13:50	Management of cytopenia after CART	Martina Pennisi (IT)
13:50-14:10	Neurological complications after CART	Roser Velasco (ES)
14:10-14:30	From CRS to HLH following CART	Matteo Doglio (IT)
14:30-14:40	Discussion	
14:40-16:00	**Session IX: Innovation in allotransplant** **Chairs: Yasmina Serroukh (NL) & Olivier Hermine (FR)**	
14:40-15:00	Invariant NKT cells and risk of GVHD	Olivier Hermine (FR)
15:00-15:25	Artificial intelligence use in allo SCT	Simona Pagliuca (FR)
15:25-15:45	Methodology and bias in registry studies	Jacques-E. Galimard (FR)
15:45-16:00	Discussion	
16:00-16:10	**Closing remarks**	
	Ali Bazarbachi (LB) & Olivier Hermine (FR)	

THANKS TO OUR SPONSORS

Sponsored Lecture

LABORATOIRES Pierre Fabre
New ways to care

Silver Partner

Takeda

Bronze Partner

AstraZeneca

Genmab